Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...

Moderately bullish activity in Moderna (MRNA), with shares up 96c, or 3.11%, near $31.82. Options volume running well above average with 111k ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

In the latest trading session, Moderna (MRNA) closed at $30.41, marking a -2.38% move from the previous day. This move lagged ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 4.0% to $43.90 Monday afternoon after the CDC reported a significant rise in acute respiratory illnesses across the U.S., driven by seasonal ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda ...